At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 132 enrolled
Drug / intervention
Etanerceptdrug
Likely dose
Etanercept 1 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-arm Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Subjects With Plaque Psoriasis
In Brief
A Phase 4 clinical trial evaluating Etanercept for Plaque Psoriasis. Completed, enrolled 132 participants across 45 sites in 2 countries.
Detailed Summary
The purpose of this study is to learn more about the immune response to etanercept produced using a modified process in patients with plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesCanada, United States
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartJan 2015
Primary CompletionNov 2015
TodayJul 2026
First PostedOct 24, 2014
Enrollment StartJan 1, 2015
Primary CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 11.7 years ago
Interventions
Etanerceptdrug
Etanercept produced using the serum free process (SFP)2 was supplied in a single-use 1 mL prefilled syringe for subcutaneous injection.